TheraRadar
← Back
Data updated: Jun 28, 2026

CATALENT

Generics

CATALENT is a generic drug manufacturer focused on Immunology.

1991
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

CATALENT's Key Drugs

CATALENT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CATALENT's Recent FDA Approvals

New NDA/BLA approvals for CATALENT over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CATALENT's Therapeutic Areas

CATALENT's approved drugs and pipeline span 1 therapeutic area, led by Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 100%
1 drugs

CATALENT's Top Competitors

CATALENT's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

CATALENT Pipeline Snapshot

Active clinical trials for CATALENT across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling